Citations

Clear

313 citation(s) found for "Alvarez, P".

269. GIANT CELL ARTERITIS WITH INTRACRANIAL VASCULITIS: A CASE SERIES
Hawkins, Alexander S., Crowson, Cynthia S. , Sánchez-Álvarez, Catalina , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Rheumatology | March 29, 2019 | Volume: 58 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kez062.043 Get It

Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Ponce, Oscar J. , Larrea-Mantilla, Laura , Hemmingsen, Bianca , Serrano, Valentina, Rodríguez‐Gutiérrez, René , Spencer‐Bonilla, Gabriela , Álvarez‐Villalobos, Neri Alejandro , Benkhadra, Khaled, Haddad, Abdullah , Brito, Juan P. , Murad, M. Hassan , Alvarez-Villalobos, Neri, Murad, Mohammad Hassan, Murad, M Hassan , Álvarez-Villalobos, Neri A , Brito, Juan P , Ponce, Oscar Josue , Gionfriddo, Michael R. , Prokop, Larry J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 23, 2019 | Volume: 104 | Issue: 5 | Pages: 1585-1594

10.1210/jc.2019-00195 | PMID 30903687 Get It

Abstract Background The efficacy of lipid-lowering agents on patient-important outcomes in older individuals is unclear. Methods We included randomized trials that enrolled individuals aged 65 years or older and that included at least 1 year of follow-up. Pairs of reviewers selected and appraised the trials. Results We included 23 trials that enrolled 60,194 elderly patients. For primary prevention, statins reduced the risk of coronary artery disease [CAD; relative risk (RR): 0.79, 95% CI: 0.68 to 0.91] and myocardial infarction (MI; RR: 0.45, 95% CI: 0.31 to 0.66) but not all-cause or cardiovascular mortality or stroke. These effects were imprecise in patients with diabetes, but there was no significant interaction between diabetes status and the intervention effect. For secondary prevention, statins reduced all-cause mortality (RR: 0.80, 95% CI: 0.73 to 0.89), cardiovascular mortality (RR: 0.68, 95% CI: 0.58 to 0.79), CAD (RR: 0.68, 95% CI: 0.61 to 0.77), MI (RR: 0.68, 95% CI: 0.59 to 0.79), and revascularization (RR: 0.68, 95% CI: 0.61 to 0.77). Intensive (vs less-intensive) statin therapy reduced the risk of CAD and heart failure. Niacin did not reduce the risk of revascularization, and fibrates did not reduce the risk of stroke, cardiovascular mortality, or CAD. Conclusion High-certainty evidence supports statin use for secondary prevention in older individuals. Evidence for primary prevention is less certain. Data in older individuals with diabetes are limited; however, no empirical evidence has shown a significant difference based on diabetes status.
A Systematic Review for Variables to Be Collected in a Transplant Database for Improving Risk Prediction
Almasri, Jehad , Tello, Mouaffaa, Benkhadra, Raed, Morrow, Allison S. , Farah, Wigdan , Álvarez‐Villalobos, Neri Alejandro , Mohammed, Khaled , Allen, Jay-Sheree , Kasiske, Bertram L. , Murad, M. Hassan , Hasan, Bashar , Alvarez Villalobos, Neri, Allen, Jay-Sheree P, Murad, Mohammad Hassan, Murad, M Hassan , Álvarez-Villalobos, Neri A , Hasan, Bashar , Prokop, Larry J. , Wang, Zhen , Israni, Ajay K. , Farah, Wigdan

Mayo Clinic

Transplantation | February 28, 2019 | Volume: 103 | Issue: 12 | Pages: 2591-2601

10.1097/tp.0000000000002652 | PMID 30768569 Get It

Background. This systematic review was commissioned to identify new variables associated with transplant outcomes that are not currently collected by the Organ Procurement and Transplantation Network (OPTN). Methods. We identified 81 unique studies including 1 193 410 patients with median follow-up of 36 months posttransplant, reporting 108 unique risk factors. Results. Most risk factors (104) were recipient related; few (4) were donor related. Most risk factors were judged to be practical and feasible to routinely collect. Relative association measures were small to moderate for most risk factors (ranging between 1.0 and 2.0). The strongest relative association measure for a heart transplant outcome with a risk factor was 8.6 (recipient with the previous Fontan operation), for a kidney transplant 2.8 (sickle cell nephropathy as primary cause of end-stage renal disease), for a liver transplant 14.3 (recipient serum ferritin >500 µg/L), and for a lung transplant 6.3 (Burkholderia cepacia complex infection for 1 y or less). OPTN may consider some of these 108 variables for future collection to enhance transplant research and clinical care. Conclusions. Evidence-based approaches can be used to determine variables collected in databases and registries. Several candidate variables have been identified for OPTN.
Laparoscopic access to the liver and application of laparoscopic microwave ablation in 2 dogs with liver neoplasia
Oramas, Alberto, Case, J. Brad , Toskich, Beau , Fox‐Alvarez, W. Alexander, Boston, Sarah E., Giglio, Robson F., Dark, Michael J. , Toskich, Beau B. , Giglio, Robson F.

Mayo Clinic

Veterinary Surgery | January 22, 2019 | Volume: 48 | Issue: S1 | Pages: No page available

10.1111/vsu.13153 | PMID 30666685 Get It

AbstractObjectiveTo determine laparoscopic accessibility of liver lobes and access to the hilus and describe laparoscopic microwave ablation (LMWA) in 2 dogs with hepatic neoplasia.Study designExperimental/descriptive case series.Sample populationSix canine cadavers and 2 clinical dogs.MethodsCadavers in dorsal recumbency underwent laparoscopic assessment of the liver. A 17 gauge MWA probe was inserted to create an ablation zone at the most proximal aspect of the hilus. The distance from the center of each ablation zone to the most proximal aspect of the corresponding hilus was determined. Two dogs with hepatic neoplasia underwent LMWA.ResultsAll lobes of the canine liver were accessible via laparoscopy. The median (interquartile range) distances from the ablation zones to the hilus for the caudate process, left lateral, left middle, quadrate, right lateral, and right middle lobes were 2.2 (1.2–2.6), 2.1 (1–4.4), 1.5 (1.4–3.7), 2, 1, 2.5 (1–4.1) cm, respectively. Histopathologic diagnoses treated by LMWA included metastatic hemangiosarcoma and primary hepatocellular carcinoma. Laparoscopic microwave ablation was technically feasible, and no complications from the procedure resulted.ConclusionLaparoscopic access to the hilus of each liver lobe is possible via a ventrodorsal approach provided reverse Trendelenburg and lateral rotation is used, especially for the right lateral lobe. Laparoscopic microwave ablation is feasible in some dogs with hepatic neoplasia. The indications for and efficacy of LMWA for hepatic neoplasia in dogs requires additional investigation.Clinical significanceLaparoscopic access to all liver lobes and MWA of some neoplastic lesions is feasible in a canine pilot study.
OPHTHALMIC VASCULAR EVENTS AFTER INTRA‐ARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA
Ancona‐Lezama, David , Lucio-Alvarez, J. Antonio , Dalvin, Lauren A. , Jabbour, Pascal , Shields, Carol L.

Mayo Clinic

Retina | September 28, 2018 | Volume: 39 | Issue: 12 | Pages: 2264-2272

10.1097/iae.0000000000002315 | PMID 30204728 Get It

Purpose: To determine whether treatment order affects ophthalmic vascular event rates after intra‐arterial chemotherapy (IAC) for retinoblastoma. Methods: Patients who received IAC as primary or secondary treatment for retinoblastoma from January 2009 to January 2018 were included. All eyes were imaged with fundus photography and fluorescein angiography. Patient characteristics and vascular event rates were compared using t-test and Fisher's exact test. Results: There were 196 patients treated with 682 infusions of IAC, divided into primary (no previous therapy, 98 eyes of 98 patients, 328 infusions) and secondary (after other therapy, 105 eyes of 98 patients, 354 infusions) treatment. Overall, ophthalmic vascular events were found after 5% of infusions (17% eyes). A comparison of ophthalmic vascular events (primary vs. secondary IAC), with mean three infusions per eye (median 3, range 1–7), revealed no difference in overall percentage of eyes affected (18% vs. 15%, P = 0.57). Adverse vascular events per eye included retinal vasculature attenuation (1% vs. 0%, P = 0.99), peripheral retinal pruning (1% vs. 0%, P = 0.99), branch retinal artery occlusion (0% vs. 1%, P = 0.99), central retinal artery occlusion (0% vs. 1%, P = 0.99), macular ischemia (0% vs. 2%, P = 0.51), vitreous hemorrhage (2% vs. 3%, P = 0.92), subretinal hemorrhage (1% vs. 0%, P = 0.99), retinal pigment epithelium atrophy (6% vs. 3% P = 0.43), choroidal atrophy (4% vs. 2%, P = 0.92), optic disk pallor (1% vs. 0%, P = 0.99), and ophthalmic artery occlusion (9% vs. 6%, P = 0.35). Conclusion: Ophthalmic vascular events after IAC for retinoblastoma affect only 5% of eyes per infusion (17% of treated eyes). Vascular event risk per eye is similar when using IAC as primary or secondary treatment.
Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review
Iqbal, Madiha , Saleem, Rabia , Jani, Prachi, Álvarez, Salvador, Ahmed, Salman , Tun, Han W. , Iqbal, Madiha , Ahmed, Salman

Mayo Clinic

Case Reports in Hematology | September 16, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/8274732 | PMID 30305967 Get It

Phlegmonous gastritis is an uncommon acute bacterial infection of the stomach that carries a fatal prognosis in spite of the advent of antibiotics. A high index of suspicion is required in patients with risk factors. An immunocompromised state is identified as one of the most important risk factors. We hereby report a case of successful antimicrobial treatment of phlegmonous gastritis in a patient who was receiving intensive chemotherapy for acute myelogenous leukemia. We have also carried out a review of literature over the past ten years. Streptococcus pyogenes is identified as the most common causative organism, and patient presentation is usually nonspecific. Conservative treatment with prompt institution of antibiotics can lead to rapid resolution in the majority of patients.
Tappas: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (AAS).
Jones, Robin L. , Attia, Steven , Liu, Lingyun , Sankhala, Kamalesh K. , Ravi, Vinod , Tap, William D. , Alvarez, Delia, Yocum, Richard C., Theuer, Charles P. , Maki, Robert G. , Maki, Robert G , Jones, Robin L , Mehta, Cyrus R. , Robinson, Steven I. , Penel, Nicolas , Stacchiotti, Silvia

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: TPS11081-TPS11081

10.1200/jco.2017.35.15_suppl.tps11081 Get It

TPS11081 Background: AAS is an aggressive soft tissue sarcoma (STS) of endothelial cell origin with an expected median overall survival of 8-12 months. Pazopanib (P) is approved for treatment of advanced STS following progression on chemotherapy. In a retrospective study of 40 AAS patients treated with single agent P the median PFS was 3.1 months and median OS 9.9 months with no complete responses. Endoglin is an essential angiogenic receptor expressed on AAS that is upregulated following VEGF inhibition, and TRC105, an endoglin antibody, given with P produced durable complete responses in AAS patients with median PFS of 5.6 months in refractory patients including those receiving prior P. The TAPPAS trial is the first randomized Phase 3 trial performed in AAS, and was initiated following protocol assistance from the EMA and Special Protocol Assessment from the FDA. Methods: TAPPAS is a randomized multicenter study of TRC105/P vs P alone in the United States and Europe that is actively enrolling cutaneous and non-cutaneous AAS patients and incorporates an adaptive enrichment design. Key inclusion criteria: 0, 1 or 2 prior lines of therapy, ECOG ≤ 1. Primary endpoint is PFS and secondary endpoints include ORR and OS. The initial sample size of 124 patients, followed until 95 PFS events, provides more than 80% power to detect a hazard ratio of 0.55. At the time of interim analysis, projected to occur upon the occurrence of 40 events in approximately 70 patients, the result will be classified as belonging to either the favorable, promising, enrichment or unfavorable zones, based on conditional power. The sample size and PFS events will be unchanged in the favorable and unfavorable zones, and will be increased to a total of 200 patients followed for 170 PFS events in the promising zone. The trial will enroll 100 additional patients, with cutaneous disease only, in the enrichment zone and will follow them until 110 events are observed in the total cutaneous population. An independent DMC will follow the trial for safety and futility. The adaptive design requires the enrollment of fewer patients, preserves type-1 error, and protects power to detect a clinically meaningful survival benefit. (NCT 02979899). Clinical trial information: NCT02979899.
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
Yuan, Zhenhua , Zhang, Dadong , Starr, Mark D. , Brady, John C. , Jivani, Manoj A., Adams, Bonne J., Alvarez, Delia, Attia, Steven , Theuer, Charles P. , Owzar, Kouros , Hurwitz, Herbert I. , Liu, Yingmiao , Choueiri, Toni K. , Nixon, Andrew B.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 11546-11546

10.1200/jco.2017.35.15_suppl.11546 Get It

11546 Background: TRC105, an endoglin-targeting monoclonal antibody with anti-angiogenic and anti-tumor activity, is being evaluated in multiple diseases. Here we report on pharmacodynamic and prognostic biomarkers in patients (pts) treated with both TRC105 and anti-VEGF agents. Methods: Plasma samples were collected from pts on three phase 2 trials combining TRC105 with an anti-VEGF agent: axitinib in metastatic renal cell carcinoma (mRCC), pazopanib in advanced soft tissue sarcoma, and bevacizumab in glioblastoma (GBM). Baseline and on-treatment levels of 22 soluble protein biomarkers were assessed. Results: Soluble endoglin markedly increased after TRC105 treatment in all pts ( p< 0.001) as previously reported. BMP9 (a ligand for endoglin) and TGFβR3 (a type III TGFβ receptor) decreased in sarcoma pts at Cycle 2 Day 1 (C2D1) and generally remained below baseline throughout the course of treatment (BMP9, p= 0.004; TGFβR3, p= 0.003). Although TGFβR3 was decreased at C2D1 in mRCC (p = 0.030), no clear patterns were observed over time. Overall BMP9 levels did not change in response to therapy in either mRCC or GBM. Osteopontin (OPN) levels, a downstream effector of TGFβ signaling, were increased in sarcoma pts [ p= 0.002 at C2D15, p< 0.001 at C4D1 and end of study (EOS)]; however, in mRCC ( p= 0.010) and GBM ( p= 0.003), OPN was only elevated at EOS. Increases in PlGF and VEGFD, and decreases in VEGFR2 were observed across all studies, as previously noted for VEGF inhibitors. In the mRCC trial, 5 of 18 pts exhibited a ≥30% tumor reduction. Lower OPN ( p= 0.026) and higher TGFβR3 ( p= 0.003) levels at baseline correlated with radiographic response to treatment. In the sarcoma trial, 6 of 19 pts responded (CHOI criteria) in which lower baseline levels of ICAM1 ( p= 0.018) and TSP2 ( p= 0.042) correlated with stable disease. Conclusions: In these trials, increases of soluble endoglin in response to TRC105 were observed, independent of the presence of any specific VEGF inhibitor. Differential regulation of BMP9, TGFβR3, and OPN suggests potential disease-specific modulation of key TGFβ signaling molecules in response to dual therapy. Baseline levels of OPN and TGFβR3 showed potential prognostic value in mRCC. Confirmation in larger trials is needed.
A phase 1B/ phase 2A study of TRC105 (Endoglin Antibody) in combination with pazopanib (P) in patients (pts) with advanced soft tissue sarcoma (STS).
Attia, Steven , Sankhala, Kamalesh K. , Riedel, Richard F. , Conry, Robert M. , Fritchie, Karen , Seon, Ben K. , Alvarez, Delia, Adams, Bonne J., Shazer, Ronald , Theuer, Charles P. , Maki, Robert G. , Maki, Robert G , Riedel, Richard F , Robinson, Steven I. , Boland, Patrick M. , Barve, Minal

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 11016-11016

10.1200/jco.2016.34.15_suppl.11016 Get It